CSL Highlights Results from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction
Read More: CSL
Shionogi Reports the Results for Ensitrelvir in P-III Trial for the Treatment of Common COVID-19 Symptoms
Read More: Shionogi
Larimar Therapeutics Highlights the P-II Results for Nomlabofusp as a Treatment for Friedreich’s Ataxia
Read More: Larimar Therapeutics
KalVista Pharmaceuticals Reports the P-III (KONFIDENT) Study Results of Sebetralstat for Treating Hereditary Angioedema
Read More: KalVista Pharmaceuticals
Otsuka Highlights P-III Study Results of AVP-786 for Treating Agitation in Patients with Dementia due to Alzheimer’s Disease
Read More: Otsuka
Replicate Bioscience Reports P-I Trial Results of RBI-4000 for Rabies
Read More: Replicate Bioscience
Sanofi Reports P-II Results for Frexalimab as a Treatment for Relapsing Multiple Sclerosis (MS)
Read More: Sanofi
Applied Therapeutics Highlights the P-III Results for Govorestat (AT-007) to Treat Sorbitol Dehydrogenase (SORD) Deficiency
Read More: Applied Therapeutics
The US FDA Accepts Humacyte’s and BLA for Human Aacelluar Vessel and Grants Priority Review for the Treatment of Vascular Trauma
Read More: Humacyte
The US FDA Granted the Fast Track Designation to GSK’s Bepirovirsen for the Treatment of Hepatitis B
Read More: GSK
The US FDA Grants BTD to AlphaMedix Developed Jointly by RadioMedix and Orano Med for Treating GEP-NETs
Read More: RadioMedix & Orano Med
Biogen’s Skyclarys (omaveloxolone) Receives the European Commission’s Approval for the Treatment of Friedreich’s Ataxia (FA)
Read More: Biogen
Takeda’s Eohilia (budesonide oral suspension) Received the US FDA’s Approval for the Treatment of Eosinophilic Esophagitis (EoE)
Read More: Takeda
The US FDA and the EMA Accepts Galderma’s BLA with Priority Review for Nemolizumab to Treat Nodularis and Atopic Dermatitis
Read More: Galderma
Ascentage Pharma Receives Clearance from the US FDA to Begin P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Leukemia
Read More: Ascentage Pharma
Diamyd Medical’s Diamyd Receives US FDA’s Fast Track Designation for Type 1 Diabetes
Read More: Diamyd Medical
The US FDA Accepts and Grants Priority Review to BMS’ sNDA for Augtyro to Treat Solid Tumors
Read More: BMS
Merit Medical Receives the US FDA’s 510(k) Clearance for SCOUT MD Surgical Guidance System to Detect and Treat Soft Tissue Cancers
Read More: Merit Medical
The MHLW Granted Priority Review to Astellas’ sNDA for Padcev and Keytruda as Combination Therapy to Treat Bladder Cancer
Read More: Astellas
For an Aggregate of ~$0.81M, RaySearch Acquires Pharmacolog’s DrugLog
Read More: RaySearch & Pharmacolog
For an Aggregate of ~$4.3B, Gilead Sciences to Acquire CymaBay Therapeutics
Read More: Gilead Sciences & CymaBay Therapeutics
Tyber Medical’s Proximal Tibia Plating System Receives the US FDA’s 510(k) Clearance
Read More: Tyber Medical
Roche Signs an Agreement with PathAI to Enhance Digital Pathology Capabilities for Companion Diagnostics
Read More: Roche & PathAI
Ono Pharmaceutical and Shattuck Labs Partner to Develop Bifunctional Fusion Proteins for Treating Autoimmune and Inflammatory Diseases
Read More: Ono Pharmaceutical & Shattuck Labs
VantAI Joins Forces with BMS to Expedite Molecular Glue Drug Discovery Through Artificial Intelligence
Read More: VantAI & BMS
Erasca Signs two Clinical Trial Collaboration and Supply Agreements with Novartis to Develop Naporafenib Combinations for Treating Solid Tumors
Read More: Erasca & Novartis
Numab Therapeutics and Ono Pharmaceutical Collaborate to Develop Multi-specific Antibody, NM49, for Treating Cancer
Read More: Numab Therapeutics & Ono Pharmaceutical
Intellia Therapeutics Signs a Collaboration Agreement ReCode Therapeutics to Develop Novel Gene Editing Therapies for Cystic Fibrosis (CF)
Read More: Intellia Therapeutics & ReCode Therapeutics
Boehringer Ingelheim and Veeva System Partner to Simplify Clinical and Regulatory Operations in Animal Health
Read More: Boehringer Ingelheim & Veeva System
Jaguar Health Receives the US FDA Approval on the Clinical Trial Protocol for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs
Read More: Jaguar Health
